Alexei G. Basnakian Data-verified

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Professor

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

36 h-index 142 pubs 4,047 cited

Research Areas

Links

ORCID Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Alexei G. Basnakian, a professor at the University of Arkansas for Medical Sciences, focuses his research on understanding disease mechanisms and evaluating potential therapeutic interventions. His work has explored the role of specific enzymes and signaling pathways in cellular processes relevant to injury and disease. For instance, he has investigated how Endonuclease G influences autophagy by modulating mTOR signaling and activating the DNA damage response. Basnakian's research also extends to evaluating the protective effects of compounds like gamma-tocotrienol against intestinal injury induced by radiation in nonhuman primate models. He has also contributed to the development and assessment of novel agents, including derivatives of benzoic acid with anti-Gram-positive bacterial activity and thiazole–androstenone derivatives for antimelanoma applications.

Furthermore, Basnakian's group has examined the potential of viruses, such as Morreton virus, as oncolytic virotherapy platforms for liver cancers. His laboratory also engages in the risk assessment of materials like carbon nanotubes for agricultural applications. With a substantial publication record (140 publications) and a high citation count (over 4,000 citations), Basnakian is recognized as a highly cited researcher. He actively leads a research group and collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Martin J. Cannon, Steven R. Post, Camila Simões, and Mulu Z. Tesfay, with whom he has co-authored numerous publications.

Metrics

h-index: 36
Publications: 142
Citations: 4,047

Selected Publications

An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates (2026)

DOI OpenAlex
Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection (2026)

DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

1 citation DOI OpenAlex
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025)

DOI OpenAlex
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2025)

DOI OpenAlex
An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates (2025)

DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

DOI OpenAlex
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)

DOI OpenAlex
Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2025)

DOI OpenAlex
The role of IGFBP-1 in the clinical prognosis and pathophysiology of acute kidney injury (2025)

1 citation DOI OpenAlex
Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2024)

DOI OpenAlex
Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss (2024)

2 citations DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

4 citations DOI OpenAlex
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024)

DOI OpenAlex
Endonuclease G (EndoG) Inhibits DNase I-Mediated Apoptosis and DNA Repair in Kidney Tubular Epithelial Cells During Cisplatin Injury (2023)

DOI OpenAlex